The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTotally Regulatory News (TLY)

Share Price Information for Totally (TLY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.25
Bid: 6.00
Ask: 6.50
Change: 1.00 (19.05%)
Spread: 0.50 (8.333%)
Open: 5.50
High: 6.25
Low: 5.50
Prev. Close: 5.25
TLY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule One - Totally plc

15 Mar 2016 07:30

RNS Number : 0974S
AIM
15 March 2016
 

 

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

Totally plc

 

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES):

 

Lighterman House

26-36 Wharfdale Road

London N1 9RY

United Kingdom

 

COUNTRY OF INCORPORATION:

 

England and Wales

 

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

 

http://www.totallyplc.com

 

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

 

Totally plc ("Totally" or the "Company") is a provider of innovative solutions to the healthcare sector, both to the National Health Service and private sector companies, to help patients better understand healthcare options, promote self-care and aid long term behavioural change which in turn impact on lifestyle and reliance on healthcare solutions. The Company achieves this principally through its wholly-owned subsidiary, Totally Health Limited, which was established in 2011 specifically to provide innovative healthcare solutions. The Company's main country of operation is the UK.

 

The Company has conditionally agreed to acquire the entire issued share capital of Premier Physical Healthcare Limited ("Premier") for a maximum consideration of £6.75 million based on the financial performance of Premier (the "Acquisition"). Pursuant to Rule 14 of the AIM Rules for Companies, the Acquisition constitutes a reverse takeover. Shareholder approval is being sought at a general meeting to approve the admission of the Company's entire issued and to be issued ordinary share capital to trading on AIM on completion of this transaction.

 

Premier is incorporated and registered in England and Wales and is a provider of physical healthcare services to both public and private patients. Since its establishment in 1997, Premier has offered physiotherapy, podiatry and ergonomics services to a variety of clients.

 

Premier provides a comprehensive range of treatments and advice for musculoskeletal injuries and conditions. Premier's clinical staff are either chartered physiotherapists, orthopaedic and rheumatology rehabilitation consultants or state registered podiatrists. The majority of Premier's revenue is derived from the provision of physiotherapy and podiatry to National Health Service patients. Premier's main country of operation is the UK.

 

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

 

Number of securities to be admitted: 19,994,953

 

Type and nominal value of the securities: Ordinary Shares of 10p each in the Company

 

Issue price: 62p per Ordinary Share

 

Shares to be held in treasury: None

 

There are no restrictions as to transfer of the securities

 

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

 

Capital to be raised on Admission: £6.20 million raised via a subscription

 

Anticipated market capitalisation on Admission: £12.40 million

 

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

 

44.55 per cent.

 

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED:

 

None

 

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

 

Robert (Bob) Holt OBE

Chairman

Wendy Jayne Lawrence

Chief Executive Officer

Donald (Don) Ahelan Baladasan

Finance Director

Anthony (Tony) Rhys Bourne

Non-Executive Director

Michael (Mike) Greig Rogers

Non-Executive Director

 

 

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

 

Before Admission

After Admission

Shareholder

Ordinary Shares

%

Ordinary Shares

%

Unicorn Asset Management Limited

900,000

9.01

4,850,000

24.26

Seneca Partners Limited

900,000

9.01

2,916,000

14.58

Schroders Plc

515,000

5.15

1,995,000

9.98

Miton Asset Management Limited

900,000

9.01

1,800,000

9.00

Optiva Securities Limited

900,000

9.01

1,198,710

6.00

Livingbridge VC LLP

900,000

9.01

900,000

4.50

Robert (Bob) Holt

600,000

6.01

800,000

4.00

 

 

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

 

Dividends of £36,450 have been paid by Premier to each of Wayne Llewellyn and Raphael Leal within the 12 months preceding the date of the admission document. Wayne Llewellyn and Raphael Leal are the Chief Executive Officer and Chief Financial Officer of Premier and are also Premier's major shareholders.

 

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

 

(i) 31 December

(ii) 30 June 2015 for Totally / 30 September 2015 for Premier

(iii) 30 June 2016 (annual report for the period ended 31 December 2015)

30 September 2016 (interim report for the period ended 30 June 2016)

30 June 2017 (annual report for the period ended 31 December 2016)

 

EXPECTED ADMISSION DATE:

 

1 April 2016

 

NAME AND ADDRESS OF NOMINATED ADVISER:

 

Allenby Capital Limited

3 St. Helen's Place

London

EC3A 6AB

United Kingdom

 

NAME AND ADDRESS OF BROKER:

 

Allenby Capital Limited

3 St. Helen's Place

London

EC3A 6AB

United Kingdom

 

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

 

Copies of the admission document, which will contain full details about the Company and the admission of its securities, will be available from the registered office of the Company and at the offices of Allenby Capital Limited, 3 St. Helen's Place, London EC3A 6AB during normal business hours on any weekday (Saturdays and public holidays excepted) for a period of one month from the date of admission.

 

The admission document will also be available to download from the Company's website www.totallyplc.com

 

DATE OF NOTIFICATION:

 

15 March 2016

 

NEW/ UPDATE:

 

NEW

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PAAEAKDSFLXKEEF
Date   Source Headline
7th May 20247:00 amRNSTrading Update
19th Apr 20245:15 pmRNSHolding(s) in Company
19th Apr 20243:00 pmRNSHolding(s) in Company
11th Mar 20247:00 amRNSContract win
7th Mar 20246:00 pmRNSHolding(s) in Company
5th Feb 20247:00 amRNSDirector/PDMR Shareholding
1st Feb 20243:00 pmRNSDirectorate Change
10th Jan 20247:00 amRNSContract Extension
8th Dec 20233:30 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSDirector/PDMR Shareholding
4th Dec 20235:45 pmRNSHolding(s) in Company
1st Dec 20239:33 amRNSDirector/PDMR Shareholding
1st Dec 20237:00 amRNSDirector/PDMR Shareholding
30th Nov 20237:00 amRNSDirector/PDMR Shareholding
28th Nov 20237:00 amRNSAdviser Update
28th Nov 20237:00 amRNSDirectorate Change
28th Nov 20237:00 amRNSInterim Results
22nd Nov 20237:00 amRNSNotice of Interim Results & Investor Presentation
4th Oct 20234:15 pmRNSHolding(s) in Company
11th Sep 202312:00 pmRNSExercise of options and change to TVR
1st Sep 202312:25 pmRNSResult of AGM
1st Sep 20237:00 amRNSAGM Statement
25th Jul 20237:00 amRNSHolding(s) in Company
18th Jul 20234:00 pmRNSExercise of options and change to TVR
13th Jul 20233:30 pmRNSHolding(s) in Company
12th Jul 202312:15 pmRNSHolding(s) in Company
12th Jul 20237:00 amRNSDividend Timetable and EPS - Corrections
11th Jul 20237:00 amRNSHolding(s) in Company
10th Jul 20237:00 amRNSPreliminary results
6th Jul 20237:00 amRNSNotice of Preliminary Results
5th Jul 20231:00 pmRNSExercise of options and change to TVR
22nd May 20237:00 amRNSTotally secures multiple contract extensions
16th May 202312:30 pmRNSExercise of options & change to TVR
2nd May 20237:01 amRNSTrading Update for 12 months ending 31 March 2023
2nd May 20237:00 amRNSAppointment of Nomad and Joint Corporate Broker
26th Apr 20237:00 amRNSFurther new contract win for urology services
18th Apr 20237:00 amRNSTotally to help reduce waiting lists in Wales
12th Apr 20237:00 amRNSTotally wins new contract for urology services
4th Apr 20237:00 amRNSTotally first to fully mobilise on NHS SVCC model
31st Mar 20235:00 pmRNSTotal Voting Rights
31st Mar 20237:00 amRNSDirector/PDMR Shareholding
20th Mar 20231:42 pmRNSExercise of options, PDMR shareholding & TVR
16th Mar 20231:34 pmRNSDirector/PDMR Shareholding
10th Mar 20231:49 pmRNSHolding(s) in Company
10th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 20232:09 pmRNSDirector/PDMR Shareholding
2nd Mar 20239:05 amRNSSecond Price Monitoring Extn
2nd Mar 20239:00 amRNSPrice Monitoring Extension
2nd Mar 20237:00 amRNSTrading Update
28th Feb 20235:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.